Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» J&J strikes potential $1B JAK inhibitor deal with Theravance
J&J strikes potential $1B JAK inhibitor deal with Theravance
J&J strikes potential $1B JAK inhibitor deal with Theravance
Submitted by
admin
on February 7, 2018 - 10:06am
Source:
Biopharma Dive
News Tags:
JNJ
JAK inhibitors
Theravance
TD-1473
drug development
Crohn's Disease
ulcerative colitis
Headline:
J&J strikes potential $1B JAK inhibitor deal with Theravance
Do Not Allow Advertisers to Use My Personal information
